Jazz Pharmaceuticals calls the tune for $172M IPO

Jazz Pharmaceuticals is planning an IPO designed to raise up to $172.5 million. Company execs evidently believe that their work in neurology and psychiatry will make their debut a positive one, even as other biotechs have run into stormy market seas. Morgan Stanley, Lehman Brothers, Credit Suisse, and Natexis Bleichroeder are handling the offering. The Palo Alto, CA-based developer launched a Phase III trial for its narcolepsy drug Xyrem as a treatment for fibromyalgia syndrome last fall.

- read the report in the IPO

ALSO: Akzo Nobel says that the IPO for Organon will proceed on March 27. Report

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.